Central nervous system metastases in patients with HER2-positive metastatic breast cancer: Incidence, treatment, and survival in patients from registHER

Clinical Cancer Research

Volumn 17, Issue 14, 2011, Pages 4834-4843

  Brufsky, Adam M ^a   Mayer, Musa ^b   Rugo, Hope S ^c   Kaufman, Peter A ^e   Tan Chiu, Elizabeth ^f   Tripathy, Debu ^g   Tudor, Iulia Cristina ^d   Wang, Lisa I ^d   Brammer, Melissa G ^d   Shing, Mona ^d   Yood, Marianne Ulcickas ^h,j   Yardley, Denise A ⁱ  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b Patient Advocate   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GENENTECH INC   (United States)

^e DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^f Florida Cancer Care   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ SARAH CANNON RESEARCH INSTITUTE   (United States)

^j BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB;

ADULT; AGE; AGED; ARTICLE; BRAIN RADIATION; BREAST CANCER; CANCER GROWTH; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROSURGERY; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; STEREOTACTIC BODY RADIATION THERAPY; THERAPY EFFECT;

ADULT; AGED; BREAST NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; RECEPTOR, ERBB-2; REGISTRIES; TIME FACTORS;

EID: 79960429096     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2962     Document Type: Article

References (29)

1. Pienkowski T, Zielinski CC. Trastuzumab treatment in patients with breast cancer and metastatic CNS disease. Ann Oncol 2010;21:917-24.
2. Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 2009;27:5278-86.
3. Miller KD, Weathers T, Haney LG, Timmerman R, Dickler M, Shen J, et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 2003;14:1072-7. (Pubitemid 36950171)
4. Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 1983;52:2349-54. (Pubitemid 14205961)
5. Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS. Breast cancer metastasis to the central nervous system. Am J Pathol 2005;167:913-20. (Pubitemid 41416243)
6. Kaal EC, Vecht CJ. CNS complications of breast cancer: current and emerging treatment options. CNS Drugs 2007;21:559-79. (Pubitemid 46984857)
7. Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 2006;24:5658-63. (Pubitemid 46631306)
8. Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 2008;19:1242-8. (Pubitemid 351911952)
9. Hall WA, Djalilian HR, Nussbaum ES, Cho KH. Long-term survival with metastatic cancer to the brain. Med Oncol 2000;17:279-86.
10. Black PM, Johnson MD. Surgical resection for patients with solid brain metastases: current status. J Neurooncol 2004;69:119-24. (Pubitemid 39256124)
11. Melisko ME, Moore DH, Sneed PK, De Franco J, Rugo HS. Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival. J Neurooncol 2008;88:359-65.
12. Mahmoud-Ahmed AS, Suh JH, Lee SY, Crownover RL, Barnett GH. Results of whole brain radiotherapy in patients with brain metastases from breast cancer: a retrospective study. Int J Radiat Oncol Biol Phys 2002;54:810-7.
13. Chang EL, Lo S. Diagnosis and management of central nervous system metastases from breast cancer. Oncologist 2003;8:398-410. (Pubitemid 37238868)
14. Alexander E 3rd, Moriarty TM, Davis RB, Wen PY, Fine HA, Black PM, et al. Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 1995;87:34-40.
15. O'Meara WP, Seidman AD, Yamada Y, McCormick B, Diamond S, Gutin PH, et al. Impact of HER2 status in breast cancer patients receiving stereotactic radiosurgery for brain metastases. J Clin Oncol 2005;23 Suppl:637.
16. Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006;107:696-704. (Pubitemid 44232661)
17. Nam BH, Kim SY, Han HS, Kwon Y, Lee KS, Kim TH, et al. Breast cancer subtypes and survival in patients with brainmetastases. Breast Cancer Res 2008;10:R20.
18. Park IH, Kwon Y, Ro JY, Lee KS, Ro J. Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue. Breast Cancer Res Treat 2010;123:125-8.
19. Lin NU. Concordance of HER2 in primary tumor and leptomeningeal metastases: now what? Breast Cancer Res Treat 2010;123:129-31.
20. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004;363:1665-72. (Pubitemid 38670323)
21. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004;22:3608-17. (Pubitemid 41103668)
22. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000;18:2349-51.
23. Stemmler HJ, Heinemann V. Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge. Oncologist 2008;13:739-50.
24. Zhang RD, Price JE, Fujimaki T, Bucana CD, Fidler IJ. Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am J Pathol 1992;141:1115-24.
25. Davies D. Blood-brain barrier breakdown and oedema formation in systemic sepsis and human brain tumours. J Anat 2002;200:528-9.
26. Papadopoulos MC, Saadoun S, Binder DK, Manley GT, Krishna S, Verkman AS. Molecular mechanisms of brain tumor edema. Neuroscience 2004;129:1011-20. (Pubitemid 39556252)
27. Gerstner ER, Fine RL. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 2007;25:2306-12.
28. Dobrogowska DH, Lossinsky AS, Tarnawski M, Vorbrodt AW. Increased blood-brain barrier permeability and endothelial abnormalities induced by vascular endothelial growth factor. J Neurocytol 1998;27:163-73. (Pubitemid 28253067)
29. Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Can Res 2010;16:5664-7.